AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03825471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colon cancer surgery
Description: laparoscopic colon cancer surgery
Study NCT02906462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early consideration of vulnerability
Description: One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
Study NCT02906462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual practices
Description: the centres applies their usual practices
Study NCT00450775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dermatix Q
Description: Dermatix Q applied twice daily
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart
Study NCT00505882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Study NCT03245229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Capsule for oral administration
Study NCT03245229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet for oral administration
Study NCT03358537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clear Liquid Diet
Description: Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
Study NCT03358537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-residue Diet
Description: Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
Study NCT02495103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
Study NCT02495103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
Study NCT02495103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib/Metformin
Description: Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
Study NCT03626571 — intervention group
Intervention type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
Study NCT03385083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count monitoring with consulting
Description: Subject counseled on step counts at initial visit and 2 and 4 weeks
Study NCT03385083 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Step count monitoring without consultation
Description: Subject counseled on step counts at initial visit
Study NCT03385083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Fitbit tracker given to participant
Study NCT03385083 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fitbit tracker
Description: Fitbit tracker given to participant
Study NCT03234309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01210287 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: nucleoside analog reverse transcriptase inhibitor
Description: tablets 100mg qd
Study NCT03037268 — intervention group
Intervention type: DEVICE
Intervention: Lytro Plenoptic Camera and 28D lens
Description: * visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader
Study NCT02285491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10ml of bupivacaine 0.5%
Description: This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
Study NCT02285491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
Study NCT02285491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
Study NCT02727192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP (CPAP or ASV)
Description: Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
Study NCT01529164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatins (Endostar)
Description: 7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
Study NCT01529164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
Study NCT01529164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 iv d1 ,repeat every 14 days
Study NCT01529164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
Study NCT01482117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: single oral administration of 300mg of clopidogrel
Study NCT01482117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: single oral administration of 100mg cilostazol
Study NCT03405636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Pulmonary Valved Conduit
Description: RVOT reconstruction
Study NCT00745576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531
Study NCT01482117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel/Cilostazol
Description: single oral administration of 300mg clopidogrel and 100mg cilostazol
Study NCT02166606 — intervention group
Intervention type: DEVICE
Intervention: ImageReady MR Conditional Pacing System Implant
Description: Implant according to standard-of-care. No study-specific interventions in that registry.
Study NCT01896934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50-200mg daily
Study NCT02277262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention
Description: The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
Study NCT02277262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct suture of the anterior abdominal wall fascia
Description: Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
Study NCT01781117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Description: Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
Study NCT01781117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation system and morcellator
Description: Holmium laser enucleation and morcellation
Study NCT01787929 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hemiarthroplasty for displaced femoral neck fractures
Description: Hemiarthroplasty is a surgery for displaced femoral neck fractures
Study NCT00796796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT00796796 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT02316457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC_W_bre1_uID
Description: vaccination
Study NCT02316457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC_W_bre1_uID/IVAC_M_uID
Description: vaccination
Study NCT03732833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into either the LCL, or both the LCL and GL.
Study NCT03732833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Study NCT01687595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HerpV and QS-21
Description: HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
Study NCT01687595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline
Study NCT05541328 — intervention group
Intervention type: OTHER
Intervention: Tisagenlecleucel
Description: The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
Study NCT01880775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: experimental
Study NCT01880775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: marcaine heavy 0.5% 7.5 mg intrathecal
Study NCT02858661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Study NCT00635466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery for rectal carcinoma
Description: Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
Study NCT01026428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide + Levodopa
Description: Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
Study NCT01026428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Levodopa
Description: Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
Study NCT01400152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Additional active warming
Description: Chemical heat pad applied to the upper torso
Study NCT03413449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty model
Description: 1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk
Study NCT04054570 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study NCT04177238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit concentrate - either cherry or blueberry
Description: Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
Study NCT04177238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit concentrate - either cherry or blueberry
Description: Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
Study NCT01129570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silybin
Description: 4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
Study NCT03005171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Thoracic epidural bupivacaine infusion
Study NCT03005171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous lidocaine infusion
Study NCT01949285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
Study NCT01949285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
Study NCT00782327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
Study NCT00782327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo capsule
Study NCT01982331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H2N2
Description: vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
Study NCT01982331 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
Study NCT02772679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyTregs+IL-2
Description: PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
Study NCT03967678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit
Study NCT03967678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit
Study NCT03967678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit
Study NCT05348135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional strength training
Description: children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
Study NCT05348135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
Study NCT05348135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy
Description: including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
Study NCT03732833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Study NCT01876758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention: Memory Training
Description: Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
Study NCT01876758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparable general mental stimulation
Description: Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
Study NCT02405793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules
Study NCT02405793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam Tablets
Study NCT01972919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
Study NCT01972919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (Gemcitabine, Capecitabine)
Description: Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
Study NCT06549868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga-based bedtime routine
Description: Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period.